Spectrum Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Spectrum Pharmaceuticals
Public
Traded as NASDAQSPPI
S&P 600 Component
Industry Pharmaceuticals
Headquarters Henderson, Nevada
Key people
R. Shrotriya, Chief Executive Officer
Website www.spectrumpharm.com

Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.

Drugs[edit]

Spectrum develops and markets drugs for treatments in oncology.

Approved drugs[edit]

  • Folotyn (pralatrexate) is an antifolate drug marketed for relapsed or refractory peripheral T-cell lymphoma.
  • Zevalin (ibritumomab) is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including patients with rituximab-refractory follicular NHL. Is is a CD-20 radio-antibody.[1]
  • Marqibo (Vincristine sulfate liposomes injection) is a sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo's approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. It was approved by the FDA in 2012.[2]
  • Beleodaq (belinostat) is an HDAC inhibitor for relapsed or refractory peripheral T-cell lymphoma.
  • Evomela (melphalan) is an alkalyating drug for multiple myeloma.[3]

In development[edit]

A number of drugs are currently investigated in clinical trials.[4]

  • Qapzola (apaziquone) is a synthetic bio-reductive prodrug intended for the treatment of non-invasive bladder cancer that is currently in Phase 3 studies. Allergan invested money in 2008 to help develop this medication further and bring it to the market.[5]
  • Rolontis (eflapegrastim) is in phase III trials for treatment of chemotherapy-induced neutropenia.[6]
  • Poziotinib is a quinazoline-based pan-HER inhibitor that blocks signaling through HER tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4). It is currently in phase II trials.

Spectrum terminated the development of Ozarelix, a luteinizing hormone releasing hormone antagonist for the treatment of benign prostatic hypertrophy in 2010.[7] Other previous drug candidates included ortataxel for the treatment of taxane-refractory tumors, and satraplatin for non-small cell lung cancer.

References[edit]

  1. ^ http://www.sppirx.com/310-spectrum-products-commercial.html
  2. ^ http://www.businesswire.com/news/home/20130903005631/en/Spectrum-Pharmaceuticals-Launches-Marqibo®-vinCRIStine-sulfate-LIPOSOME
  3. ^ http://www.sppirx.com/310-spectrum-products-commercial.html
  4. ^ Clinical trials
  5. ^ Marcial G. "Cancer drugs from Spectrum". Businessweek, June 15, 2009: 67. 
  6. ^ https://clinicaltrials.gov/ct2/show/NCT02643420
  7. ^ http://www.businesswire.com/news/home/20100127005863/en/Spectrum-Pharmaceuticals-Terminates-Ozarelix-Development-Program-Benign

External links[edit]